Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study

PURPOSE: The Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio predicts benefit from extended endocrine therapy in hormone receptor–positive (HR(+)) early-stage breast cancer. Here, we report the final analysis of the Trans-aTTom study examining BCI (H/I)'s predictive performance. EXPERIMENTA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, John M.S., Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C., Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena F., Pirrie, Sarah J., Schnabel, Catherine A., Rea, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306281/
https://www.ncbi.nlm.nih.gov/pubmed/35144966
http://dx.doi.org/10.1158/1078-0432.CCR-21-3385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306281/
https://www.ncbi.nlm.nih.gov/pubmed/35144966
http://dx.doi.org/10.1158/1078-0432.CCR-21-3385

Ejemplares similares